Pexidartinib (hydrochloride)
Pexidartinib hydrochloride (PLX-3397 hydrochloride) is a potent, orally active, selective, and ATP-competitive colony stimulating factor 1 receptor (CSF1R or M-CSFR) and c-Kit inhibitor, with IC50s of 20 and 10 nM, respectively. Pexidartinib hydrochloride exhibits 10- to 100-fold selectivity for c-Kit and CSF1R over other related kinases. Pexidartinib hydrochloride induces cell apoptosis and has anti-cancer activity[1].
Product Specifications
CAS Number
[2040295-03-0]
Product Name Alternative
PLX-3397 (hydrochloride)
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; c-Fms; c-Kit
Type
Reference compound
Related Pathways
Apoptosis; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/pexidartinib-hydrochloride.html
Purity
99.77
Solubility
DMSO : 60 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL (ultrasonic)
Smiles
FC(C1=CC=C(CNC2=NC=C(CC3=CNC4=NC=C(Cl)C=C43)C=C2)C=N1)(F)F.Cl
Molecular Formula
C20H16Cl2F3N5
Molecular Weight
454.28
Precautions
H302, H315, H319, H335
References & Citations
[1]DeNardo DG, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011 Jun;1 (1) :54-67.|[2]Kuse Y, et al. Microglia increases the proliferation of retinal precursor cells during postnatal development. Mol Vis. 2018 Jul 30;24:536-545. eCollection 2018.|[3]Lee JH, et al. A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors. Invest New Drugs. 2019 Mar 2.|[4]Merry TL, et al. The CSF1 receptor inhibitor pexidartinib (PLX3397) reduces tissue macrophage levels without affecting glucose homeostasis in mice. Int J Obes (Lond) . 2020;44 (1) :245-253.|[5]Luo L, et al. Intermittent theta-burst stimulation improves motor function by inhibiting neuronal pyroptosis and regulating microglial polarization via TLR4/NFκB/NLRP3 signaling pathway in cerebral ischemic mice. J Neuroinflammation. 2022 Jun 11;19 (1) :141.|[6]Chadarevian JP, et al. Engineering an inhibitor-resistant human CSF1R variant for microglia replacement. J Exp Med. 2023 Mar 6;220 (3) :e20220857.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Launched
Citation 01
Autophagy. 2025 Jul;21 (7) :1523-1543.|Biomolecules. 2022 May 4;12 (5) :666.|bioRxiv. 2025 Aug 28.|JCI Insight. 2025 Jul 1;10 (15) :e184465.|Universität zu Köln. 2023 Sep 26.|University of Cambridge. 2025|ACS Nano. 2024 Jan 30;18 (4) :3295-3312.|Acta Neuropathol Commun. 2025 May 19;13 (1) :105.|Adv Sci (Weinh) . 2024 Dec 12:e2413451.|Adv Sci (Weinh) . 2024 Dec 5:e2410360.|Aging Cell. 2025 Sep 19:e70228.|Am J Physiol Cell Physiol. 2020 Sep 1;319 (3) :C605-C610.|Anti-Cancer Drug. 2022 Dec.|Behav Pharmacol. 2023 Sep 1;34 (6) :318-329.|Biochem Pharmacol. 2022 Apr:198:114952.|Biomedicines. 2021 Oct 4;9 (10) :1387.|Biomedicines. 2022 Jul 9;10 (7) :1653.|bioRxiv. 2023 Jul 25.|bioRxiv. 2023 Nov 14:2023.11.10.566510.|bioRxiv. 2023 Nov 17:2023.11.16.567274.|bioRxiv. 2023 Oct 12.|bioRxiv. 2024 Apr 14.|bioRxiv. 2024 Apr 16.|bioRxiv. 2024 Jun 6:2024.06.05.597614.|bioRxiv. 2024 October 02.|bioRxiv. 2024 September 21.|bioRxiv. 2025 Jan 19:2025.01.19.633810.|bioRxiv. 2025 Jul 17:2025.07.12.664223.|bioRxiv. 2025 Jun 7:2025.06.04.657911.|bioRxiv. 2025 Nov 13:2025.11.12.688147.|bioRxiv. 2025 Nov 24:2025.11.21.689833.|bioRxiv. 2025 Oct 13.|BMC Med. 2023 Aug 4;21 (1) :286.|Brain Behav Immun. 2023 Jan:107:153-164.|Brain Behav. 2025 Mar;15 (3) :e70369.|Cancer Cell. 2021 Oct 11;39 (10) :1361-1374.e9.|Cancer Cell. 2023 Nov 13;41 (11) :1911-1926.e8.|Cancer Lett. 2022 Sep 1:543:215795.|Cell Oncol (Dordr) . 2021 Feb;44 (1) :193-204.|Cell Rep Med. 2025 Jun 23:102204.|Cell Rep. 2023 Sep 22;42 (10) :113128.|Cell Rep. 2024 Oct 23;43 (11) :114894.|Cell Stem Cell. 2025 Jan 2;32 (1) :86-104.e7.|Cell Stem Cell. 2025 Jun 5;32 (6) :914-934.e8.|Cells. 2021 Apr 12;10 (4) :874.|Cells. 2021 Jul 22;10 (8) :1862.|Chem Biol Interact. 2023 Jan 5:369:110255.|Circ Res. 2021 Sep 17;129 (7) :e121-e140.|CNS Neurosci Ther. 2023 Jun;29 Suppl 1 (Suppl 1) :146-160.|Dev Cell. 2025 Apr 21;60 (8) :1199-1216.e7.|Diabetes. 2023 Nov 1;72 (11) :1692-1706.|EMBO Mol Med. 2024 Dec;16 (12) :3113-3141.|Endocrinology. 2024 Feb 20;165 (4) :bqae003.|eNeuro. 2023 Nov 10;10 (11) :ENEURO.0323-23.2023.|Eur J Immunol. 2024 Dec;54 (12) :e2451139.|Front Immunol. 2022 May 13;13:866073.|Glia. 2021 Apr;69 (4) :943-953.|Glia. 2021 Jun;69 (6) :1494-1514.|Glia. 2022 Nov;70 (11) :2032-2044.|Inflamm Regen. 2024 Jun 6;44 (1) :30.|Int Dent J. 2025 Jun 2;75 (4) :100843.|Int Immunopharmacol. 2023 May:118:109976.|Int Immunopharmacol. 2025 Apr 16:152:114428.|Int Immunopharmacol. 2026 Jan 1;168 (Pt 1) :115828.|Int J Mol Sci. 2024 Jun 26;25 (13) :7001.|Interdiscip Med. 2025 Feb 24.|Invest Ophthalmol Vis Sci. 2025 Mar 3;66 (3) :4.|J Am Heart Assoc. 2023 Jun 20;12 (12) :e029053.|J Anat. 2023 Sep;243 (3) :394-403.|J Ethnopharmacol. 2025 Jan 31:340:119287.|J Exp Med. 2023 Mar 6;220 (3) :e20220857.|J Immunother Cancer. 2025 Jul 15;13 (7) :e010926.|J Mol Neurosci. 2025 Aug 2;75 (3) :97.|J Neuroinflammation. 2020 Jan 23;17 (1) :31.|J Neuroinflammation. 2022 Jan 21;19 (1) :20.|J Neuroinflammation. 2023 Feb 25;20 (1) :51.|J Neuroinflammation. 2024 Nov 14;21 (1) :295.|J Neuroinflammation. 2024 Oct 21;21 (1) :270.|J Neuroinflammation. 2024 Sep 1;21 (1) :215.|J Neuroinflammation. 2025 Aug 1;22 (1) :197.|J Neuroinflammation. 2025 Mar 5;22 (1) :67.|J Neurooncol. 2021 Jun;153 (2) :225-237.|J Neurosci Res. 2021 Aug;99 (8) :1940-1956.|J Neurosci. 2020 May 6;40 (19) :3862-3879.|J Ocul Pharmacol Ther. 2020 Jun;36 (5) :311-319.|Karolinska Institutet. Dept of Clinical Neuroscience. 2021 Feb.|Life Sci Alliance. 2023 Aug 7;6 (11) :e202302020.|Life Sci. 2020 Oct 1;258:118099.|Life Sci. 2025 Apr 9:123627.|Methods Mol Biol. 2018:1711:351-398.|Mol Pharmacol. 2022 Jun;101 (6) :381-389.|Mol Ther. 2025 Nov 12.|Mol Ther. 2025 Nov 12:S1525-0016 (25) 00872-X.|Molecules. 2022 Jan 4;27 (1) :297.|Nat Biomed Eng. 2018 Aug;2 (8) :578-588.|Nat Cardiovasc Res. 2023 Jun;2 (6) :572-586.|Nat Commun. 2024 Jul 5;15 (1) :5654.|Nat Commun. 2024 Oct 13;15 (1) :8837.|Nat Immunol. 2023 May;24 (5) :827-840.|Nat Metab. 2024 Aug;6 (8) :1479-1491.|Nat Neurosci. 2025 Jul;28 (7) :1404-1417.|Nature. 2022 Mar;603 (7899) :138-144.|Nature. 2024 Apr;628 (8006) :145-153.|Neural Regen Res. 2023 Sep;18 (9) :2067-2074.|Neuron. 2021 Aug 18;109 (16) :2573-2589.e9.|Neuropharmacology. 2019 Jun:151:33-44.|Neuropharmacology. 2020 Aug 1;172:108132.|Patent. US20230203500A1.|Patent. US20250002920A1.|Pharmacol Res. 2023 May:191:106773.|Phytomedicine. 2025 Nov 29:150:157636.|Prog Neuropsychopharmacol Biol Psychiatry. 2020 Jul 13;101:109931.|Reprod Biol Endocrinol. 2025 Oct 22;23 (1) :135.|Res Sq. 2023 Sep 12:rs.3.rs-3263412.|Res Sq. 2024 Nov 19.|Res Sq. 2024 Sep 03.|Res Sq. 2025 Feb 10.|Research Square Preprint. 2021 Sep.|Research Square Preprint. 2022 Jul.|Research Square Preprint. 2024 Feb 15.|Research Square Print. 2022 Jun.|Sci Rep. 2021 Aug 6;11 (1) :15989.|Sci Rep. 2024 Aug 4;14 (1) :18031.|SSRN. 2023 Jun 29.|STAR Protoc. 2023 Jul 29;4 (3) :102490.|The Ohio State University. 2023 Oct.|Theranostics. 2020 Jan 1;10 (1) :74-90.|Transl Psychiatry. 2020 Jan 27;10 (1) :32.|Transl Psychiatry. 2024 Aug 23;14 (1) :338.|Transl Psychiatry. 2025 Aug 15;15 (1) :285.|Transl Stroke Res. 2025 Aug;16 (4) :1075-1093.|Universität zu Köln. 2023 Sep 26.|University of Washington. 2024.|University of Washington. 2025.
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
